Sutimlimab Cad denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sutimlimab cad are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Applies Step Therapy to Sutimlimab — and Why You Can Challenge It

Sutimlimab targets the complement pathway to treat cold agglutinin disease (CAD), a rare cause of chronic hemolytic anemia. BCBS step-therapy protocols typically require documentation that a patient has tried — and not adequately responded to — one or more less expensive treatments before sutimlimab will be approved. Because CAD is rare and its treatment options are limited, this protocol often does not map cleanly onto your clinical history.

## Why This Denial Is Appealable

Step-therapy requirements must have a medical exception pathway. If your prescriber can document that prior treatments are contraindicated, clinically inappropriate, or were already tried and failed, BCBS is required to waive the step. Many states also have step-therapy override laws that set strict timelines for plan response.

Your federal appeal rights: - Internal appeal (ACA §2719 / ERISA §503): File within 180 days of the denial. The plan must provide a full-and-fair review and cannot simply restate that the step was not completed. - External review: Available after internal exhaustion (or deemed exhaustion). An independent review organization decides; the window is generally up to four months from final internal denial. - Expedited review: Available in 72 hours if delay poses serious health risk — relevant if you are actively hemolyzing.

## What to Gather

• Treatment history with dates and outcomes: For each prior therapy the plan requires, document the start date, stop date, dose range tried, and reason for discontinuation (inadequate response, adverse event, or clinical contraindication). Vague statements are insufficient — use chart notes, labs, and visit records.
• Lab trend data: Hemoglobin trajectory, reticulocyte count, bilirubin, and cold agglutinin titer over time to demonstrate disease activity and prior-treatment failure.
• Specialist diagnosis letter: Confirmation of CAD diagnosis from a hematologist, explaining the limited treatment landscape for this specific condition.
• Prescriber medical-necessity letter: Should address each step-therapy requirement explicitly — either confirming the step was completed or invoking the exception pathway with clinical reasoning.
• BCBS coverage policy: Request the current version. Note every listed step and every listed exception criterion.

## Criteria-Mapping Structure

For each therapy listed in the step protocol, create a table row:

| Step Required by Policy | Patient's History | Evidence | |---|---|---| | [Prior therapy A] | Tried from [date] to [date]; discontinued due to [outcome] | Chart note, lab, prescriber letter | | [Prior therapy B] | Clinically inappropriate because [reason per chart] | Specialist attestation |

Your appeal letter should methodically work through each step, providing the specific chart evidence. Conclude by citing the medical exception provision in BCBS's own policy. If internal appeal is denied, request external review — IROs frequently overturn step-therapy denials for rare diseases where the protocol was not designed with CAD in mind.